Cargando…

Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses

INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunger-Baldauf, Cornelia, Nakasato, Priscila, Noviello, Stephanie, Whelan, Sarah, Bieth, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964916/
https://www.ncbi.nlm.nih.gov/pubmed/35044647
http://dx.doi.org/10.1007/s40744-021-00422-9
_version_ 1784678316248137728
author Dunger-Baldauf, Cornelia
Nakasato, Priscila
Noviello, Stephanie
Whelan, Sarah
Bieth, Bruno
author_facet Dunger-Baldauf, Cornelia
Nakasato, Priscila
Noviello, Stephanie
Whelan, Sarah
Bieth, Bruno
author_sort Dunger-Baldauf, Cornelia
collection PubMed
description INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based analyses were conducted on endpoints from studies of canakinumab in both patient populations. The objective was to further support the efficacy of canakinumab in patients with AOSD. METHODS: A Bayesian analysis of endpoints from a study of canakinumab in AOSD was conducted borrowing information from five pooled sJIA studies using a robust meta-analytic predictive (MAP) approach. Similarity of clinical outcomes across populations was fulfilled if the AOSD study posterior median fell within the 95% predicted credible interval for the outcome of interest, based on the pooled sJIA data. Population model-based analyses (pharmacokinetic [PK] and PK/pharmacodynamic [PKPD]) were conducted to compare the pharmacokinetics and exposure–response relationships between populations. RESULTS: The AOSD study posterior medians for adapted American College of Rheumatology (ACR)30 response, continuous adapted ACR response, number of active joints, C-reactive protein, and absence of fever were within the 95% credible interval for the prediction of the MAP analysis from the pooled sJIA data, supporting the similarity in outcomes between patient populations. PK analysis demonstrated comparable exposure across sJIA age groups and patients with AOSD. PKPD relationships were consistent across patient populations. Analyses indicated that no therapeutic benefit can be expected from a dose increase in patients with AOSD. CONCLUSION: The analyses presented support the similarity of clinical outcomes following treatment with canakinumab in patients with sJIA and AOSD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00422-9.
format Online
Article
Text
id pubmed-8964916
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-89649162022-04-12 Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses Dunger-Baldauf, Cornelia Nakasato, Priscila Noviello, Stephanie Whelan, Sarah Bieth, Bruno Rheumatol Ther Brief Report INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based analyses were conducted on endpoints from studies of canakinumab in both patient populations. The objective was to further support the efficacy of canakinumab in patients with AOSD. METHODS: A Bayesian analysis of endpoints from a study of canakinumab in AOSD was conducted borrowing information from five pooled sJIA studies using a robust meta-analytic predictive (MAP) approach. Similarity of clinical outcomes across populations was fulfilled if the AOSD study posterior median fell within the 95% predicted credible interval for the outcome of interest, based on the pooled sJIA data. Population model-based analyses (pharmacokinetic [PK] and PK/pharmacodynamic [PKPD]) were conducted to compare the pharmacokinetics and exposure–response relationships between populations. RESULTS: The AOSD study posterior medians for adapted American College of Rheumatology (ACR)30 response, continuous adapted ACR response, number of active joints, C-reactive protein, and absence of fever were within the 95% credible interval for the prediction of the MAP analysis from the pooled sJIA data, supporting the similarity in outcomes between patient populations. PK analysis demonstrated comparable exposure across sJIA age groups and patients with AOSD. PKPD relationships were consistent across patient populations. Analyses indicated that no therapeutic benefit can be expected from a dose increase in patients with AOSD. CONCLUSION: The analyses presented support the similarity of clinical outcomes following treatment with canakinumab in patients with sJIA and AOSD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00422-9. Springer Healthcare 2022-01-19 /pmc/articles/PMC8964916/ /pubmed/35044647 http://dx.doi.org/10.1007/s40744-021-00422-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Brief Report
Dunger-Baldauf, Cornelia
Nakasato, Priscila
Noviello, Stephanie
Whelan, Sarah
Bieth, Bruno
Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
title Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
title_full Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
title_fullStr Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
title_full_unstemmed Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
title_short Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
title_sort similar clinical outcomes in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease treated with canakinumab: bayesian and population model-based analyses
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964916/
https://www.ncbi.nlm.nih.gov/pubmed/35044647
http://dx.doi.org/10.1007/s40744-021-00422-9
work_keys_str_mv AT dungerbaldaufcornelia similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses
AT nakasatopriscila similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses
AT noviellostephanie similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses
AT whelansarah similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses
AT biethbruno similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses